Clinical outcomes for COVID-19 in lung transplant recipients (LTRs): an insight from the early Omicron wave

This study aims to investigate the short-term impact of COVID-19 on LTRs in a real-life setting. High mortality, low seroconversion rates, persistent high viral loads, drug interactions, and evolving resistance are concerns in this population. Among 118 LTRs, 68 patients were diagnosed with COVID-19 from January 2022 to March 2023, resulting in an incidence rate of 57%. Retrospective clinical data retrieved from electronic medical records were used in this observational study, approved by the local ethics committee, and analyzed using SPSS Version 28. The cohort's characteristics and outcomes are detailed in the tables. SARS-CoV-2 infection persists prevalent, yet a trend toward lower mortality is observed. Hospitalization, involving prolonged length of stay and additional treatments, is common. Older age, lower BMI, low antibody titers, and tacrolimus use, as opposed to a combination of tacrolimus/sirolimus, were statistically associated with the presence of COVID-19 pneumonia. The limited sample size precludes reaching further conclusions. Long-term outcomes remain uncertain, making ongoing epidemiological monitoring essential. <fig><object-id>erj;64/suppl_68/PA4997/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig> <fig><object-id>erj;64/suppl_68/PA4997/F2</object-id><object-id>F2</object-id><object-id>F2</object-id><graphic></graphic></fig>